Dr. Wang represents pharmaceutical companies, life sciences venture capital funds, biotechnology innovators and other life sciences organizations in licensing, collaboration, co-development and co-commercialization transactions. He advises on the structuring and negotiation of strategic alliances and intellectual property-driven transactions across the sector, from research-stage collaborations through commercial licensing, cross-border biotech “NewCo” transactions and other complex life sciences transactions.
He also holds a PhD in biological chemistry, providing him with additional perspective on the scientific and technical considerations involved in life sciences transactions. Fluent in both Mandarin and English, he also advises clients in China and internationally on acquisitions, licensing and commercialization of innovative pharmaceutical products worldwide, with particular experience in the growing cross-border transactions involving such products developed in mainland China.
- Represented Envisagenics on Collaboration and License Agreement for Up To $1 Billion With Boehringer Ingelheim International GmbH.*
- Represented AriBio Co. Ltd in a collaboration with Fosun Pharma for AriBio’s late-phase Alzheimer’s disease program, including, among others, a US$60 million option payment to AriBio and an additional US$80 million payment to secure Fosun’s expanded rights under the program.*
- Represented Harbour BioMed (Shanghai) Co. Ltd on its license agreement and equity partnership with Solstice Oncology, with upfront consideration to Harbour Biomed valued at over US$105 million and additional milestone payments up to approximately US$1.1 billion.*
- Represented GluBio Therapeutics in its US$30 million strategic investment from Sanofi to advance molecular glue degraders for Sickle Cell Disease.*
- Represented Harbour BioMed in its strategic collaboration with Bristol Meyers Squib to discover and develop next-generation multi-specific antibodies for payments totaling US$90 million as well as development and commercial milestones of up to US$1.035 billion, along with tiered royalties.*
- Represented Harbour BioMed its global strategic collaboration for up to US$670 million with Otsuka Pharmaceutical Co., Ltd.*
- Advised Septerna on its exclusive global collaboration and license agreement with Novo Nordisk for up to US$2.2 billion.*
- Advised Oak Hill Bio in an exclusive license agreement with Roche to obtain global rights for an antisense oligonucleotides product, rugonersen.*
- Advised Harbour BioMed on a global strategic collaboration with AstraZeneca to discover and develop next-generation multi-specific antibodies with US$175 million near term payments as well as up to US$4.4 billion milestone payments and royalties.*
- Represented Multitude Therapeutics in its license agreement with Adcendo ApS for the development of a first-in-class ADC targeting Tissue Factor, with up to US$1 billion in upfront and milestone payments.*
- Represented MabCare Therapeutics in its exclusive license agreement with Day One Biopharmaceuticals for development and commercialization of MabCare’s solid tumor ADC with US$55 million upfront and up to US$1.15 billion in potential milestone payments.*
- Represented Arvinas in an exclusive license agreement with Novartis Pharma for development and commercialization of PROTAC, androgen receptor degrader for patients with prostate cancer, with US$150 million upfront and up to US$1.01 billion in potential milestone payments.*
- Represented Oak Hill Bio in a license and development agreement with Chiesi Group to develop, manufacture and commercialize OHB-607, a recombinant version of insulin-like growth factor-1 (IGF-1) product.*
- Represented Teva Pharmaceuticals in a collaboration with Sanofi to co-develop and co-commercialize Teva’s anti-TL1A antibody product, with US$500 million upfront payment and up to US$1 billion in development and launch milestones payments.*
- Represented Orionis Biosciences in a collaboration with Genetech to discover and develop molecular glue class medicines, with an upfront US$47 million payment and a potential of more than US$2 billion development, commercial and sales milestone payments.*
- Represented Multitude Therapeutics in a licensing collaboration with OnCusp Therapeutics for the development and commercialization of a potentially highly differentiated second-in-class CDH6 antibody drug conjugate.*
- Represented Karuna Therapeutics in a strategic collaboration with Zai lab for development, manufacturing, and commercialization of KarXT in Greater China, with US$35 million upfront payment and up to US$80 million in development and regulatory milestones and US$72 million in sales milestones payments.*
- Advised Arvinas in its global collaboration agreement with Pfizer to develop and commercialize ARV-471 with US$650 million upfront payment and US$350 million equity investment in Arvinas from Pfizer, and a potential US$1.4 billion in milestone payments.*
*Experience prior to joining Clifford Chance.
News and client work
Contact details
- Clifford Chance, New York
- +12128788253
- Email me
Career & qualifications
- Peking University (BS) 2006
- Washington University in St. Louis (PhD) 2011
- Cornell Law School (JD) 2014
- Admitted as Attorney-at-law in New York 2015
- Joined Clifford Chance as partner 2026
Professional bodies
- New York State Bar Association
Awards and citations
- Recognized by The Best Lawyers in America Ones to Watch for his work in Intellectual Property Law 2022
- Cornell Law Review